acne vulgaris. Acne vulgaris
Conditions
Interventions
Intervention 1: Intervention group: Topical preparation containing spironolactone nanoparticles (NLC) coated by chitosan (1%), will prepared as emulgel. The preparation will package and add code lab
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
13 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients with mild to moderate acne, defined as a score of 1 to 30 on the global acne grading system (GAGS) scale. Patients which received no previous acne therapies participated in the study, or have not received any treatment before this study
Exclusion criteria
Exclusion criteria: Patients which received topical anti-acne therapy two months before or during the study or any systemic therapy with antibiotics, OCP, retinoid, and spironolactone before or during the study Patients were excluded if they had other disease; Pregnant, or planning to become pregnant women Lactating
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| No. of lesions. Timepoint: At the beginning of study (time zero) and 2, 4 and 8 weeks after treatment. Method of measurement: clinical evaluation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lesion kind (inflammatory or non-inflammatory). Timepoint: At the beginning of study (time zero) and 2, 4 and 8 weeks after treatment. Method of measurement: Clinical evaluation. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Saeedi
Mazandaran University of Medical Sciences
Outcome results
None listed